Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SYNLOGIC, INC.SYBX · Entity 7801 | Director | June 22, 2023 | June 26, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SYNLOGIC, INC.
Report date June 22, 2023 · Filed June 26, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.50 · Expires 2033-06-22 | Direct | 30,000 |
Reported balance
After 2023-06-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-22 · Grant · Acquired 30,000 · Balance 30,000 F1: The option vests and becomes exercisable in full on the earlier of (A) the first anniversary of the date of grant or (B) immediately prior to the next annual meeting of the Corporation's stockholders after the date of grant, subject to the non-employee director's continued service as a director of the Corporation. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and becomes exercisable in full on the earlier of (A) the first anniversary of the date of grant or (B) immediately prior to the next annual meeting of the Corporation's stockholders after the date of grant, subject to the non-employee director's continued service as a director of the Corporation.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
2seventy bio, Inc.
Report date May 13, 2025 · Filed May 15, 2025
Section 16 reporting ended · disclosed 2025-05-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2025-05-13 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-05-13 · Disposition to issuer · Disposed 335,964 · Balance 897,642 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 10, 2025, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Daybreak Merger Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $5.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of May 13, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent (the "Merger"). F2: Pursuant to the terms of the Merger Agreement, each share of Company Common Stock subject to issuance pursuant to outstanding restricted stock units (each, a "Company RSU Award"), whether vested or unvested that was outstanding immediately prior to the effective time of the Merger (the "Effective Time"), became fully vested, and was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company RSU Award, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the Merger Consideration. Row 2 · 2025-05-13 · Other · Disposed 897,642 · Balance 0 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 10, 2025, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Daybreak Merger Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $5.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of May 13, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent (the "Merger"). F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Company Common Stock was tendered in exchange for the Merger Consideration, without interest and subject to any withholding of taxes required by applicable law. |
| Common StockSEC Table I · non-derivative | IndirectNick Leschly 2001 Trust | 0 |
Reported balance
After 2025-05-13 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2025-05-13 · Other · Disposed 15,233 · Balance 0 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 10, 2025, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Daybreak Merger Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $5.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of May 13, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent (the "Merger"). F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Company Common Stock was tendered in exchange for the Merger Consideration, without interest and subject to any withholding of taxes required by applicable law. |
| Common StockSEC Table I · non-derivative | IndirectNick Leschly Irrevocable GST Trust of 2019 | 0 |
Reported balance
After 2025-05-13 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2025-05-13 · Other · Disposed 41,000 · Balance 0 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 10, 2025, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Daybreak Merger Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $5.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of May 13, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent (the "Merger"). F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Company Common Stock was tendered in exchange for the Merger Consideration, without interest and subject to any withholding of taxes required by applicable law. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.97 | Direct | 0 |
Reported balance
After 2025-05-13 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-05-13 · Disposition to issuer · Disposed 469,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. Each Company Option, whether vested or unvested, that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 10, 2025, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Daybreak Merger Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $5.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of May 13, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent (the "Merger").
F2: Pursuant to the terms of the Merger Agreement, each share of Company Common Stock subject to issuance pursuant to outstanding restricted stock units (each, a "Company RSU Award"), whether vested or unvested that was outstanding immediately prior to the effective time of the Merger (the "Effective Time"), became fully vested, and was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company RSU Award, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the Merger Consideration.
F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Company Common Stock was tendered in exchange for the Merger Consideration, without interest and subject to any withholding of taxes required by applicable law.
F4: Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. Each Company Option, whether vested or unvested, that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration.
bluebird bio, Inc.
Report date May 30, 2025 · Filed June 03, 2025
Section 16 reporting ended · disclosed 2025-06-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2025-06-02 transaction · row 4
2 source rows · reconciled sequenceRow 1 · 2025-05-30 · Other · Disposed 14,416 · Balance 1,245 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of February 21, 2025 (as amended, the "Merger Agreement"), by and among the Issuer, Beacon Parent Holdings, L.P. ("Parent") and Beacon Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. Tendering stockholders were given the option to receive per share consideration of either (x) $3.00 in cash per share, subject to any applicable withholding taxes and without interest thereon, plus one contingent value right ("CVR") per share, representing the right to receive one contingent payment of $6.84, in cash, subject to any applicable withholding taxes and without interest thereon, upon achievement of the specified milestone or (y) $5.00 in cash per share, subject to any applicable withholding taxes and without interest thereon (collectively, the "Offer Price"). F2: (Continued from footnote 1) After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger"), effective as of June 2, 2025 (the "Effective Time"), with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent. Row 4 · 2025-06-02 · Disposition to issuer · Disposed 1,245 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each time-based restricted stock unit award with respect to shares that is, at the time of determination, subject to vesting or forfeiture conditions and that is not a PSU Award (as defined below) (but including, for clarity, any PSU Award that is subject solely to service-based vesting conditions as of the Effective Time) ("RSU Award") that is outstanding as of immediately prior thereto, shall (a) accelerate and become fully vested, and (b) by virtue of the Merger automatically (except as otherwise provided in the Merger Agreement) and without any action on the part of the Issuer, Parent or the holder thereof, be canceled and terminated and converted into the right to receive F4: (Continued from footnote 1) (i) an amount in cash equal to the product of the number of shares underlying such RSU Award immediately prior to the Effective Time and $3.00 in cash, subject to any applicable withholding taxes and without interest thereon plus (ii) one CVR with respect to each share subject to such RSU Award immediately prior to the Effective Time. |
| Common StockSEC Table I · non-derivative | IndirectNick Leschly 2001 Trust | 0 |
Reported balance
After 2025-05-30 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2025-05-30 · Other · Disposed 2,284 · Balance 0 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of February 21, 2025 (as amended, the "Merger Agreement"), by and among the Issuer, Beacon Parent Holdings, L.P. ("Parent") and Beacon Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. Tendering stockholders were given the option to receive per share consideration of either (x) $3.00 in cash per share, subject to any applicable withholding taxes and without interest thereon, plus one contingent value right ("CVR") per share, representing the right to receive one contingent payment of $6.84, in cash, subject to any applicable withholding taxes and without interest thereon, upon achievement of the specified milestone or (y) $5.00 in cash per share, subject to any applicable withholding taxes and without interest thereon (collectively, the "Offer Price"). F2: (Continued from footnote 1) After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger"), effective as of June 2, 2025 (the "Effective Time"), with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent. |
| Common StockSEC Table I · non-derivative | IndirectNick Leschly Irrevocable GST Trust of 2019 | 0 |
Reported balance
After 2025-05-30 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2025-05-30 · Other · Disposed 6,150 · Balance 0 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of February 21, 2025 (as amended, the "Merger Agreement"), by and among the Issuer, Beacon Parent Holdings, L.P. ("Parent") and Beacon Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. Tendering stockholders were given the option to receive per share consideration of either (x) $3.00 in cash per share, subject to any applicable withholding taxes and without interest thereon, plus one contingent value right ("CVR") per share, representing the right to receive one contingent payment of $6.84, in cash, subject to any applicable withholding taxes and without interest thereon, upon achievement of the specified milestone or (y) $5.00 in cash per share, subject to any applicable withholding taxes and without interest thereon (collectively, the "Offer Price"). F2: (Continued from footnote 1) After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger"), effective as of June 2, 2025 (the "Effective Time"), with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the terms of an Agreement and Plan of Merger, dated as of February 21, 2025 (as amended, the "Merger Agreement"), by and among the Issuer, Beacon Parent Holdings, L.P. ("Parent") and Beacon Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. Tendering stockholders were given the option to receive per share consideration of either (x) $3.00 in cash per share, subject to any applicable withholding taxes and without interest thereon, plus one contingent value right ("CVR") per share, representing the right to receive one contingent payment of $6.84, in cash, subject to any applicable withholding taxes and without interest thereon, upon achievement of the specified milestone or (y) $5.00 in cash per share, subject to any applicable withholding taxes and without interest thereon (collectively, the "Offer Price").
F2: (Continued from footnote 1) After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger"), effective as of June 2, 2025 (the "Effective Time"), with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent.
F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each time-based restricted stock unit award with respect to shares that is, at the time of determination, subject to vesting or forfeiture conditions and that is not a PSU Award (as defined below) (but including, for clarity, any PSU Award that is subject solely to service-based vesting conditions as of the Effective Time) ("RSU Award") that is outstanding as of immediately prior thereto, shall (a) accelerate and become fully vested, and (b) by virtue of the Merger automatically (except as otherwise provided in the Merger Agreement) and without any action on the part of the Issuer, Parent or the holder thereof, be canceled and terminated and converted into the right to receive
F4: (Continued from footnote 1) (i) an amount in cash equal to the product of the number of shares underlying such RSU Award immediately prior to the Effective Time and $3.00 in cash, subject to any applicable withholding taxes and without interest thereon plus (ii) one CVR with respect to each share subject to such RSU Award immediately prior to the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 02, 2025 Filed Jun 3, 2025 17:18 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Disposition to issuerCommon Stock | 1,245 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-081115 · ownership.xml · nonDerivative · entry 4 Leschly Nick · CIK 0001578408 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F3 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each time-based restricted stock unit award with respect to shares that is, at the time of determination, subject to vesting or forfeiture conditions and that is not a PSU Award (as defined below) (but including, for clarity, any PSU Award that is subject solely to service-based vesting conditions as of the Effective Time) ("RSU Award") that is outstanding as of immediately prior thereto, shall (a) accelerate and become fully vested, and (b) by virtue of the Merger automatically (except as otherwise provided in the Merger Agreement) and without any action on the part of the Issuer, Parent or the holder thereof, be canceled and terminated and converted into the right to receive F4 · price: (Continued from footnote 1) (i) an amount in cash equal to the product of the number of shares underlying such RSU Award immediately prior to the Effective Time and $3.00 in cash, subject to any applicable withholding taxes and without interest thereon plus (ii) one CVR with respect to each share subject to such RSU Award immediately prior to the Effective Time. Read SEC document |
| May 30, 2025 Filed Jun 3, 2025 17:18 UTC | bluebird bio, Inc. BLUE · Entity 78923 | OtherCommon Stock | 6,150 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-081115 · ownership.xml · nonDerivative · entry 3 Leschly Nick · CIK 0001578408 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Nick Leschly Irrevocable GST Trust of 2019 Disclosed balance after: 0 F1 · price: In connection with the terms of an Agreement and Plan of Merger, dated as of February 21, 2025 (as amended, the "Merger Agreement"), by and among the Issuer, Beacon Parent Holdings, L.P. ("Parent") and Beacon Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. Tendering stockholders were given the option to receive per share consideration of either (x) $3.00 in cash per share, subject to any applicable withholding taxes and without interest thereon, plus one contingent value right ("CVR") per share, representing the right to receive one contingent payment of $6.84, in cash, subject to any applicable withholding taxes and without interest thereon, upon achievement of the specified milestone or (y) $5.00 in cash per share, subject to any applicable withholding taxes and without interest thereon (collectively, the "Offer Price"). F2 · price: (Continued from footnote 1) After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger"), effective as of June 2, 2025 (the "Effective Time"), with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent. Read SEC document |
| May 30, 2025 Filed Jun 3, 2025 17:18 UTC | bluebird bio, Inc. BLUE · Entity 78923 | OtherCommon Stock | 2,284 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-081115 · ownership.xml · nonDerivative · entry 2 Leschly Nick · CIK 0001578408 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Nick Leschly 2001 Trust Disclosed balance after: 0 F1 · price: In connection with the terms of an Agreement and Plan of Merger, dated as of February 21, 2025 (as amended, the "Merger Agreement"), by and among the Issuer, Beacon Parent Holdings, L.P. ("Parent") and Beacon Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. Tendering stockholders were given the option to receive per share consideration of either (x) $3.00 in cash per share, subject to any applicable withholding taxes and without interest thereon, plus one contingent value right ("CVR") per share, representing the right to receive one contingent payment of $6.84, in cash, subject to any applicable withholding taxes and without interest thereon, upon achievement of the specified milestone or (y) $5.00 in cash per share, subject to any applicable withholding taxes and without interest thereon (collectively, the "Offer Price"). F2 · price: (Continued from footnote 1) After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger"), effective as of June 2, 2025 (the "Effective Time"), with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent. Read SEC document |
| May 30, 2025 Filed Jun 3, 2025 17:18 UTC | bluebird bio, Inc. BLUE · Entity 78923 | OtherCommon Stock | 14,416 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-081115 · ownership.xml · nonDerivative · entry 1 Leschly Nick · CIK 0001578408 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,245 F1 · price: In connection with the terms of an Agreement and Plan of Merger, dated as of February 21, 2025 (as amended, the "Merger Agreement"), by and among the Issuer, Beacon Parent Holdings, L.P. ("Parent") and Beacon Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. Tendering stockholders were given the option to receive per share consideration of either (x) $3.00 in cash per share, subject to any applicable withholding taxes and without interest thereon, plus one contingent value right ("CVR") per share, representing the right to receive one contingent payment of $6.84, in cash, subject to any applicable withholding taxes and without interest thereon, upon achievement of the specified milestone or (y) $5.00 in cash per share, subject to any applicable withholding taxes and without interest thereon (collectively, the "Offer Price"). F2 · price: (Continued from footnote 1) After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger"), effective as of June 2, 2025 (the "Effective Time"), with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent. Read SEC document |
| May 13, 2025 Filed May 15, 2025 16:35 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | Disposition to issuerStock Options (Right to buy) · Derivative | 469,000 | Not disclosed Strike: $3.97 | Not disclosed |
DisclosureSEC source: 0001562180-25-003887 · primarydocument.xml · derivative · entry 5 Leschly Nick · CIK 0001578408 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 469,000 shares Expires not disclosed F4 · kind: Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. Each Company Option, whether vested or unvested, that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration. F4 · price: Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. Each Company Option, whether vested or unvested, that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. Each Company Option, whether vested or unvested, that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. Each Company Option, whether vested or unvested, that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration. Read SEC document |
| May 13, 2025 Filed May 15, 2025 16:35 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | OtherCommon Stock | 41,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-25-003887 · primarydocument.xml · nonDerivative · entry 4 Leschly Nick · CIK 0001578408 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Nick Leschly Irrevocable GST Trust of 2019 Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 10, 2025, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Daybreak Merger Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $5.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of May 13, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent (the "Merger"). F3 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Company Common Stock was tendered in exchange for the Merger Consideration, without interest and subject to any withholding of taxes required by applicable law. Read SEC document |
| May 13, 2025 Filed May 15, 2025 16:35 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | OtherCommon Stock | 15,233 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-25-003887 · primarydocument.xml · nonDerivative · entry 3 Leschly Nick · CIK 0001578408 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Nick Leschly 2001 Trust Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 10, 2025, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Daybreak Merger Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $5.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of May 13, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent (the "Merger"). F3 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Company Common Stock was tendered in exchange for the Merger Consideration, without interest and subject to any withholding of taxes required by applicable law. Read SEC document |
| May 13, 2025 Filed May 15, 2025 16:35 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | OtherCommon Stock | 897,642 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-25-003887 · primarydocument.xml · nonDerivative · entry 2 Leschly Nick · CIK 0001578408 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 10, 2025, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Daybreak Merger Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $5.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of May 13, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent (the "Merger"). F3 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Company Common Stock was tendered in exchange for the Merger Consideration, without interest and subject to any withholding of taxes required by applicable law. Read SEC document |
| May 13, 2025 Filed May 15, 2025 16:35 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | Disposition to issuerCommon Stock | 335,964 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-25-003887 · primarydocument.xml · nonDerivative · entry 1 Leschly Nick · CIK 0001578408 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 897,642 F1 · kind: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 10, 2025, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Daybreak Merger Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $5.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of May 13, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent (the "Merger"). F2 · price: Pursuant to the terms of the Merger Agreement, each share of Company Common Stock subject to issuance pursuant to outstanding restricted stock units (each, a "Company RSU Award"), whether vested or unvested that was outstanding immediately prior to the effective time of the Merger (the "Effective Time"), became fully vested, and was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company RSU Award, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the Merger Consideration. Read SEC document |
| January 06, 2025 Filed Jan 7, 2025 16:42 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | SaleCommon Stock | 892 | $2.78 | $2,478.42 |
DisclosureSEC source: 0001562180-25-000245 · primarydocument.xml · nonDerivative · entry 2 Leschly Nick · CIK 0001578408 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,233,606 F1 · kind: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of restricted stock units. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.76 to $2.785, inclusive. The Reporting Person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 16:42 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | SaleCommon Stock | 85,978 | $2.94 | $252,422.81 |
DisclosureSEC source: 0001562180-25-000245 · primarydocument.xml · nonDerivative · entry 1 Leschly Nick · CIK 0001578408 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,234,498 F1 · kind: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.87 to $3.01, inclusive. The Reporting Person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 06, 2024 Filed Nov 8, 2024 16:09 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantStock Option (right to buy) · Derivative | 49,850 | $0.00 Strike: $0.44 | $0.00 |
DisclosureSEC source: 0001562180-24-007609 · primarydocument.xml · derivative · entry 4 Leschly Nick · CIK 0001578408 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,850 Underlying: Common Stock · 49,850 shares Expires 2034-11-06 F2 · derivative.exercise_date: This option vests 100% on the earlier of November 6, 2025 or the date of the next annual meeting of stockholders. Read SEC document |
| November 06, 2024 Filed Nov 8, 2024 16:09 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantCommon Stock | 24,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-007609 · primarydocument.xml · nonDerivative · entry 1 Leschly Nick · CIK 0001578408 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 315,839 F1 · security: These restricted stock units for common stock vest 100% on the earlier of November 6, 2025 or the date of the next annual meeting of stockholders. Read SEC document |
| January 08, 2024 Filed Jan 9, 2024 16:08 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | GrantStock Option (Right to buy) · Derivative | 469,000 | $0.00 Strike: $3.97 | $0.00 |
DisclosureSEC source: 0001562180-24-000364 · primarydocument.xml · derivative · entry 5 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 469,000 Underlying: Common Stock · 469,000 shares Expires 2034-01-08 F4 · derivative.exercise_date: This stock option vests over a four-year period at the rate of 25% on 01/02/2025, and then in 36 equal monthly installments thereafter. Read SEC document |
| January 08, 2024 Filed Jan 9, 2024 16:08 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | GrantCommon Stock | 235,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-000364 · primarydocument.xml · nonDerivative · entry 2 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,320,476 F3 · security: RSU awards vest over a four-year period at the rate of 25% on 01/02/2025, 25% on 01/02/2026, 25% on 01/02/2027, and 25% on 01/02/2028. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 16:08 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | SaleCommon Stock | 1,554 | $3.75 | $5,833.09 |
DisclosureSEC source: 0001562180-24-000364 · primarydocument.xml · nonDerivative · entry 1 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,085,476 F1 · kind: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of restricted stock units ("RSUs"). F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.675 to $3.83, inclusive. The Reporting Person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 16:30 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | SaleCommon Stock | 72,312 | $3.87 | $279,738.97 |
DisclosureSEC source: 0001562180-24-000305 · primarydocument.xml · nonDerivative · entry 1 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,087,030 F1 · kind: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.83 to $3.96, inclusive. The Reporting Person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 22, 2023 Filed Aug 24, 2023 17:04 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | SaleCommon Stock | 9,312 | $5.49 | $51,090.29 |
DisclosureSEC source: 0001562180-23-006560 · primarydocument.xml · nonDerivative · entry 1 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,159,342 F1 · kind: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.46 to $5.535, inclusive. The Reporting Person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 03, 2023 Filed Aug 7, 2023 16:07 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | SaleCommon Stock | 9,060 | $6.13 | $55,498.84 |
DisclosureSEC source: 0001562180-23-006222 · primarydocument.xml · nonDerivative · entry 1 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,168,654 F1 · kind: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.06 to $6.23, inclusive. The Reporting Person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: The Form 4 filed on July 19, 2022 inadvertently understated the Reporting Person's holdings by 133,500 shares, an error that was carried forward on subsequent filings. Column 5 of Table I reflects the number of shares of Issuer common stock beneficially owned by the Reporting Person following the reported transactions as of August 7, 2023. Read SEC document |
| June 22, 2023 Filed Jun 26, 2023 18:25 UTC | SYNLOGIC, INC. SYBX · Entity 7801 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0000950170-23-029808 · ownership.xml · derivative · entry 1 Leschly Nick · CIK 0001578408 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2033-06-22 F1 · derivative.exercise_date: The option vests and becomes exercisable in full on the earlier of (A) the first anniversary of the date of grant or (B) immediately prior to the next annual meeting of the Corporation's stockholders after the date of grant, subject to the non-employee director's continued service as a director of the Corporation. Read SEC document |
| June 16, 2023 Filed Jun 20, 2023 16:31 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantStock Option (right to buy) · Derivative | 21,600 | $0.00 Strike: $3.81 | $0.00 |
DisclosureSEC source: 0001562180-23-005350 · primarydocument.xml · derivative · entry 4 Leschly Nick · CIK 0001578408 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,600 Underlying: Common Stock · 21,600 shares Expires 2033-06-16 F2 · derivative.exercise_date: This option vests 100% on the earlier of June 16, 2024 or the date of the next annual meeting of stockholders. Read SEC document |
| June 16, 2023 Filed Jun 20, 2023 16:31 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantCommon Stock | 10,790 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-005350 · primarydocument.xml · nonDerivative · entry 1 Leschly Nick · CIK 0001578408 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 290,939 F1 · security: These restricted stock units for common stock vest 100% on the earlier of June 16, 2024 or the date of the next annual meeting of stockholders. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 16:59 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | GrantStock Option (Right to buy) · Derivative | 162,500 | $0.00 Strike: $13.20 | $0.00 |
DisclosureSEC source: 0001562180-23-000949 · primarydocument.xml · derivative · entry 5 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,500 Underlying: Common Stock · 162,500 shares Expires 2033-02-01 F3 · derivative.exercise_date: This stock option vests over a four-year period at the rate of 25% on 01/01/2024, and then in 36 equal monthly installments thereafter. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 16:59 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | GrantCommon Stock | 428,571 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-000949 · primarydocument.xml · nonDerivative · entry 2 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,044,214 F2 · security: This restricted stock unit award vests over a three-year period at the rate of 40% on 01/01/2024, 40% on 01/01/2025, and 20% on 01/01/2026. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 16:59 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | GrantCommon Stock | 81,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-000949 · primarydocument.xml · nonDerivative · entry 1 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 615,643 F1 · security: This restricted stock unit award vests over a four-year period at the rate of 25% on 01/01/2024, 25% on 01/01/2025, 25% on 01/01/2026, and 25% on 01/01/2027. Read SEC document |
| January 12, 2023 Filed Jan 17, 2023 16:30 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | SaleCommon Stock | 6,587 | $10.46 | $68,889.48 |
DisclosureSEC source: 0001562180-23-000444 · primarydocument.xml · nonDerivative · entry 1 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 536,419 F1 · kind: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.35 to $10.52, inclusive. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 11, 2023 Filed Jan 13, 2023 16:19 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 4,290 | $7.80 | $33,480.45 |
DisclosureSEC source: 0001562180-23-000407 · primarydocument.xml · nonDerivative · entry 1 Leschly Nick · CIK 0001578408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,149 F1 · kind: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F2 · price: The range in prices for the transaction reported on this line was $7.61 to $7.93. The average weighted price was $7.8043. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 11, 2023 Filed Jan 18, 2023 17:18 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | SaleCommon Stock | 2,026 | $10.63 | $21,532.53 |
DisclosureSEC source: 0001562180-23-000483 · primarydocument.xml · nonDerivative · entry 1 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 534,393 F1 · kind: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.25 to $10.78, inclusive. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 09, 2023 Filed Jan 11, 2023 16:23 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | SaleCommon Stock | 2,979 | $10.33 | $30,787.07 |
DisclosureSEC source: 0001562180-23-000355 · primarydocument.xml · nonDerivative · entry 1 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 543,006 F1 · kind: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.19 to $10.48, inclusive. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 05, 2022 Filed Aug 8, 2022 17:08 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | SaleCommon Stock | 5,499 | $16.23 | $89,262.52 |
DisclosureSEC source: 0001562180-22-005949 · primarydocument.xml · nonDerivative · entry 1 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 545,985 F1 · kind: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.39 to $16.71, inclusive. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 15, 2022 Filed Jul 19, 2022 16:22 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | SaleCommon Stock | 5,404 | $13.81 | $74,628.70 |
DisclosureSEC source: 0001562180-22-005709 · primarydocument.xml · nonDerivative · entry 1 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 551,484 F1 · kind: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.63 to $14.07, inclusive. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 22, 2022 Filed Jun 23, 2022 18:09 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $4.46 | $0.00 |
DisclosureSEC source: 0001562180-22-005339 · primarydocument.xml · derivative · entry 4 Leschly Nick · CIK 0001578408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2032-06-22 F2 · derivative.exercise_date: This option vests 100% on the earlier of June 22, 2023 or the date of the next annual meeting of stockholders. Read SEC document |
| June 22, 2022 Filed Jun 23, 2022 18:09 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantCommon Stock | 3,109 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-005339 · primarydocument.xml · nonDerivative · entry 1 Leschly Nick · CIK 0001578408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,439 F1 · security: These restricted stock units for common stock vest 100% on the earlier of June 22, 2023 or the date of the next annual meeting of stockholders. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 20:15 UTC | SYNLOGIC, INC. SYBX · Entity 7801 | GrantStock Option (right to buy) · Derivative | 27,000 | $0.00 Strike: $1.17 | $0.00 |
DisclosureSEC source: 0000899243-22-022181 · doc4.xml · derivative · entry 1 Leschly Nick · CIK 0001578408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2032-06-09 F1 · derivative.exercise_date: The option vests and becomes exercisable in full on the earlier of (A) the first anniversary of the date of grant or (B) immediately prior to the next annual meeting of the Corporation's stockholders after the date of grant, subject to the non-employee director's continued service as a director of the Corporation. Read SEC document |
| March 17, 2022 Filed Mar 21, 2022 17:07 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | GrantCommon Stock | 368,857 | $12.20 | $4,500,055.40 |
DisclosureSEC source: 0001562180-22-002846 · primarydocument.xml · nonDerivative · entry 1 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 556,888 F1 · shares: The shares of common stock were acquired by the Reporting Person pursuant to a share purchase agreement in a private placement offering of shares of the Issuer's common stock, which offering closed on March 17, 2022. The issuance of such shares by the Reporting Person was approved by the Issuer's board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| March 17, 2022 Filed Mar 22, 2022 16:55 UTC Amendment | 2seventy bio, Inc. TSVT · Entity 79756 | PurchaseCommon Stock | 368,857 | $12.20 | $4,500,055.40 |
DisclosureSEC source: 0001562180-22-002863 · primarydocument.xml · nonDerivative · entry 1 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 556,888 F1 · shares: The shares of common stock were acquired by the Reporting Person pursuant to a share purchase agreement in a private placement offering of shares of the Issuer's common stock, which offering closed on March 17, 2022. The issuance of such shares by the Reporting Person was approved by the Issuer's board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| March 01, 2022 Filed May 5, 2022 20:36 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | GrantStock Option (Right to buy) · Derivative | 267,000 | $0.00 Strike: $13.41 | $0.00 |
DisclosureSEC source: 0001562180-22-003848 · primarydocument.xml · derivative · entry 4 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,000 Underlying: Common Stock · 267,000 shares Expires 2032-03-01 F2 · derivative.exercise_date: This stock option vests over a four-year period at the rate of 25% on 01/01/2023 and then in 36 equal monthly installments thereafter. Read SEC document |
| March 01, 2022 Filed May 5, 2022 20:36 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | GrantCommon Stock | 133,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-003848 · primarydocument.xml · nonDerivative · entry 1 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 690,388 F1 · security: Restricted stock unit awards vest over a four-year period at the rate of 25% on 01/01/2023, 25% on 01/01/2024, 25% on 01/01/2025, and 25% on 01/01/2026. Read SEC document |
| January 11, 2022 Filed Jan 12, 2022 21:15 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 5,068 | $9.64 | $48,868.70 |
DisclosureSEC source: 0001562180-22-000442 · primarydocument.xml · nonDerivative · entry 2 Leschly Nick · CIK 0001578408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,330 F1 · kind: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F3 · price: The range in prices for the transaction reported on this line was $9.48 to $9.83. The average weighted price was $9.6426. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 10, 2022 Filed Jan 12, 2022 21:15 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 2,369 | $9.40 | $22,273.81 |
DisclosureSEC source: 0001562180-22-000442 · primarydocument.xml · nonDerivative · entry 1 Leschly Nick · CIK 0001578408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,398 F1 · kind: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F2 · price: The range in prices for the transaction reported on this line was $9.385 to $9.42. The average weighted price was $9.4022. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 07, 2022 Filed Jan 11, 2022 17:32 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | SaleCommon Stock | 3,270 | $23.91 | $78,178.51 |
DisclosureSEC source: 0001562180-22-000409 · primarydocument.xml · nonDerivative · entry 1 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,031 F1 · kind: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.75 to $24.28, inclusive. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 11, 2021 Filed Nov 16, 2021 06:43 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | GrantStock Option (right to buy) · Derivative | 57,957 | $0.00 Strike: $44.17 | $0.00 |
DisclosureSEC source: 0001628280-21-023470 · wf-form4_163706292470660.xml · derivative · entry 16 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,957 Underlying: Common Stock · 57,957 shares Expires 2031-02-16 F12 · shares: Represents options to purchase shares of 2seventy's common stock granted to the reporting person in connection with the Separation (see footnotes 2 and 3). F17 · derivative.exercise_date: This option vests over a four-year period, at a rate of 25% on 01/04/2022 and in 36 equal monthly installments thereafter (see footnotes 2 and 3). Read SEC document |
| November 11, 2021 Filed Nov 16, 2021 06:43 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | GrantStock Option (right to buy) · Derivative | 21,331 | $0.00 Strike: $114.67 | $0.00 |
DisclosureSEC source: 0001628280-21-023470 · wf-form4_163706292470660.xml · derivative · entry 15 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,331 Underlying: Common Stock · 21,331 shares Expires 2030-03-02 F12 · shares: Represents options to purchase shares of 2seventy's common stock granted to the reporting person in connection with the Separation (see footnotes 2 and 3). F16 · derivative.exercise_date: This option vests over a four-year period, at a rate of 25% on 01/04/2021 and in 36 equal monthly installments thereafter (see footnotes 2 and 3). Read SEC document |
| November 11, 2021 Filed Nov 16, 2021 06:43 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | GrantStock Option (right to buy) · Derivative | 32,817 | $0.00 Strike: $209.06 | $0.00 |
DisclosureSEC source: 0001628280-21-023470 · wf-form4_163706292470660.xml · derivative · entry 14 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,817 Underlying: Common Stock · 32,817 shares Expires 2029-02-01 F12 · shares: Represents options to purchase shares of 2seventy's common stock granted to the reporting person in connection with the Separation (see footnotes 2 and 3). F15 · derivative.exercise_date: This option vests over a four-year period, at a rate of 25% on 01/04/2020 and in 36 equal monthly installments thereafter (see footnotes 2 and 3). Read SEC document |
| November 11, 2021 Filed Nov 16, 2021 06:43 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | GrantStock Option (right to buy) · Derivative | 39,381 | $0.00 Strike: $318.73 | $0.00 |
DisclosureSEC source: 0001628280-21-023470 · wf-form4_163706292470660.xml · derivative · entry 13 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,381 Underlying: Common Stock · 39,381 shares Expires 2028-02-01 F12 · shares: Represents options to purchase shares of 2seventy's common stock granted to the reporting person in connection with the Separation (see footnotes 2 and 3). F14 · derivative.exercise_date: This option vests over a four-year period, at a rate of 25% on 01/04/2019 and in 36 equal monthly installments thereafter (see footnotes 2 and 3). Read SEC document |
| November 11, 2021 Filed Nov 16, 2021 06:43 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | GrantStock Option (right to buy) · Derivative | 36,099 | $0.00 Strike: $117.40 | $0.00 |
DisclosureSEC source: 0001628280-21-023470 · wf-form4_163706292470660.xml · derivative · entry 12 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,099 Underlying: Common Stock · 36,099 shares Expires 2027-02-01 F12 · shares: Represents options to purchase shares of 2seventy's common stock granted to the reporting person in connection with the Separation (see footnotes 2 and 3). F13 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof (see footnotes 2 and 3). Read SEC document |
| November 11, 2021 Filed Nov 16, 2021 06:43 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | GrantStock Option (right to buy) · Derivative | 29,535 | $0.00 Strike: $78.44 | $0.00 |
DisclosureSEC source: 0001628280-21-023470 · wf-form4_163706292470660.xml · derivative · entry 11 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,535 Underlying: Common Stock · 29,535 shares Expires 2026-03-01 F12 · shares: Represents options to purchase shares of 2seventy's common stock granted to the reporting person in connection with the Separation (see footnotes 2 and 3). F13 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof (see footnotes 2 and 3). Read SEC document |
| November 11, 2021 Filed Nov 16, 2021 06:43 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | GrantStock Option (right to buy) · Derivative | 54,149 | $0.00 Strike: $151.25 | $0.00 |
DisclosureSEC source: 0001628280-21-023470 · wf-form4_163706292470660.xml · derivative · entry 10 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,149 Underlying: Common Stock · 54,149 shares Expires 2025-03-02 F12 · shares: Represents options to purchase shares of 2seventy's common stock granted to the reporting person in connection with the Separation (see footnotes 2 and 3). F13 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof (see footnotes 2 and 3). Read SEC document |
| November 11, 2021 Filed Nov 16, 2021 06:43 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | GrantStock Option (right to buy) · Derivative | 54,149 | $0.00 Strike: $38.00 | $0.00 |
DisclosureSEC source: 0001628280-21-023470 · wf-form4_163706292470660.xml · derivative · entry 9 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,149 Underlying: Common Stock · 54,149 shares Expires 2024-03-03 F12 · shares: Represents options to purchase shares of 2seventy's common stock granted to the reporting person in connection with the Separation (see footnotes 2 and 3). F13 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof (see footnotes 2 and 3). Read SEC document |
| November 11, 2021 Filed Nov 16, 2021 06:43 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | GrantCommon Stock | 50,425 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-21-023470 · wf-form4_163706292470660.xml · nonDerivative · entry 6 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,301 F2 · security: bluebird equity awards granted prior to January 1, 2021 were converted into equity awards of both bluebird and 2seventy. The number of shares underlying the converted bluebird equity awards was determined by multiplying the number of shares underlying the existing bluebird equity award by a fraction, the numerator of which is the volume-weighted average trading price of bluebird common stock (trading "regular way") on the five trading days immediately prior to the distribution date (the "bluebird Pre-Distribution VWAP"), the denominator of which is the sum of (1) the volume-weighted average trading price of 2seventy common stock (trading "regular way") on the five trading days immediately following the distribution date (the "2seventy VWAP") multiplied by the distribution ratio and (2) the volume-weighted average trading price of bluebird common stock (trading "regular way") on the five trading days immediately following the distribution date (the "bluebird Post-Distribution VWAP"). F3 · security: The number of shares underlying the converted 2seventy equity awards was determined by multiplying the number of shares underlying the existing bluebird equity awards by a fraction, the numerator of which is the bluebird Pre-Distribution VWAP and the denominator of which is the sum of (1) the 2seventy VWAP multiplied by the distribution ratio and (2) the quotient obtained by dividing the bluebird Post-Distribution VWAP by the distribution ratio. bluebird equity awards granted on or after January 1, 2021, such equity awards were converted into 2seventy equity awards. The number of shares of 2seventy common stock underlying such converted equity awards is equal to the number of shares of bluebird common stock subject to the equity award immediately prior to the distribution multiplied by a fraction, the numerator of which is the bluebird Pre-Distribution VWAP and the denominator of which is the 2seventy VWAP. F8 · security: In connection with the Separation, the reporting person received a grant of restricted stock units, each representing the right to receive a share of 2seventy's common stock, as a result of the adjustment of existing bluebird restricted stock units prior to the Separation (see footnotes 2 and 3). This restricted stock unit award vests upon the satisfaction of certain performance criteria. F9 · balance_after: Includes 81,685 shares of 2seventy's common stock received in a pro rata distribution by bluebird as a result of the Separation. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.